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ABSTRACT:
Rat liver microsomal testosterone (250 mM) hydroxylation and im-
munoreactive CYP3A protein were compared after administration
of the antiglucocorticoid RU 486 (50 mgzkg21zday21 for 4 days) and
the hypocholesterolaemic drug SR-12813 (150 mgzkg21zday21 for 4
days). Markers of CYP3A-mediated enzyme activity (testosterone
15b-, 6b-, and 2b-hydroxylation) were increased after administra-
tion of both drugs. Testosterone 6b-hydroxylation was increased
5-fold by RU 486 and 9-fold by SR-12813. Administration of dexa-
methasone alone at 150 mgzkg21zday21 or in combination with RU
486 induced testosterone 6b-hydroxylation 15- to 20-fold. The lack
of antagonistic effect of RU 486 on dexamethasone-mediated
CYP3A induction strengthens support for the hypothesis that the
“classical glucocorticoid receptor” does not play a part in this
process. The induction of CYP3A enzymes by the bisphosphonate
SR-12813 suggests the existence of a new class of compounds
with CYP3A inducing properties.
The cytochrome P4503A subfamily of enzymes has a major role in
drug oxidation in man because of abundant hepatic expression (1) and
wide substrate specificity (2). CYP3A enzymes are also inducible by
numerous structurally unrelated compounds leading to a number of
drug-drug interactions resulting from increased substrate clearance by
the induced CYP3A enzyme (3–6).
Investigations into the inducibility of CYP3A enzymes in mamma-
lian species (in the rat, in particular), reviewed by Guzelian (7)
revealed four classes of structurally unrelated inducers, namely, the
steroids (which include synthetic glucocorticoids and anti-glucocorti-
coids), phenobarbital-type inducers (anti-convulsants, organochlorine
pesticides, and PCBs), macrolide antibiotics, and antifungal com-
pounds (imidazoles). The structural diversity of these compounds
suggests that multiple mechanisms may be responsible for induction
of the CYP3A genes. More recently, the HMG-CoA reductase inhib-
itors have been identified as a fifth group of inhibitors which have
been shown to induce CYP3A enzymes in a number of mammalian
species (pravastatin in man, (8) and lovastatin in the rat (9)).
The results in this paper describe the effects of the antiglucocorti-
coid RU 486 (proprietary name mifepristone) and the hypocholester-
olaemic drug SR-12813 (fig. 1) on the hepatic CYP3A levels in the
female ratin vivo, where testosterone 15b-, 6b-, and 2b-hydroxyla-
tion were used as selective markers of CYP3A enzyme activity (10,
11), and immunoblot analysis of liver microsomal samples was car-
ried out with polyclonal goat anti-rabbit CYP3A antibodies.
Materials and Methods
Materials. All solvents were of HPLC grade obtained from BDH (Poole,
UK) and Rathburn Chemicals, Ltd. (Walkerburn, Scotland) and were vacuum
filtered through 45mm filters (Millipore, Ireland) before use. Testosterone,
b-mercaptoethanol, glycerol, Pyronin Y, sodium dodecyl sulfate, and dexa-
methasone were purchased from Sigma Chemical Co. (Poole, Dorset, UK). RU
486 and SR-12813 were gifts from Roussel Uclaf (Paris) and Symphar Phar-
maceuticals, respectively. Hydroxytestosterone metabolites were purchased
from Steraloids Inc. (Wilton, NH). Polyclonal anti-CYP3A antibodies for
W stern immunoblotting were gifts donated by Dr. Colin Henderson, Univer-
sity of Dundee.
Animals. Female Sprague-Dawley rats (250–300 g) were housed under
conditions of 12 hr light-12 hr darkness cycle for at least 1 week before use and
fed CRM diet (Special Diet Services, Witham, Essex, UK).
Administration of drugs. RU 486 (50mgzkg21zday21 for 4 days) and
SR-12813 (150mgzkg21zday21 for 4 days) were dissolved in olive oil
(1mlzkg21) before ip administration. Dexamethasone was dissolved in 0.9%
(w/v) saline and administered at 150mgzk 21zday21 for 4 days. After overnight
fasting, animals were killed on the fifth day and liver microsomes prepared
immediately.
Preparation of liver microsomes.After cervical dislocation, livers were
placed in washing buffer. After removal of nonhepatic tissue, the liver was
placed in homogenization buffer (43 weight of the washing buffer). The liver
was scissor-minced and homogenized with 7 strokes of a motor driven plastic
pestle in a glass vessel (Elvehejm-Potter). The homogenate was then centri-
fuged at 15,000g for 20 min. The supernatant was decanted and centrifuged at
180,000g for 60 min. The pellet was washed in homogenizing buffer and
centrifuged at 180,000g (30 min.). The washed pellet was resuspended in
storage buffer at a concentration of 20–60mgz l21 and was stored at2135°C.
Protein content was determined according to the method of Lowry et al. (12).
Testosterone hydroxylation in liver microsomes.The assay methodology
was based on that described by Sonderfan (10). Microsomal incubations were
performed in 10-ml screw-top, round bottomed glass tubes (BDH Ltd., Poole,
UK). All glassware was silanised using Repelcote (BDH). Testosterone (25ml
of a 10 mM solution in methanol) was added in the test tube and was followed
by testosterone metabolism buffer (TMB, 50 mM phosphate buffer, pH 7.4
containing 5 mM MgCl2) and microsomal protein (1 mg) to make a final
volume of 750ml. The tubes were than shaken in a water bath (37°C) for 5 min
before the reaction volume was made up to a total of 1ml by addition of freshly
prepared NADPH generating system (0.8 mg NADP, 1.6 mg isocitric acid, 1
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unit isocitrate dehydrogenase and 100ml .1 M MgSO4, and was made up to
250ml with TMB). The reaction was allowed to proceed in a shaking water
bath for 5 min before termination of the reaction by the addition of ice cold
dichloromethane (6 ml) and the addition of internal standard (100ml of a 10
mgzml21 solution of 11b-hydroxytestosterone in methanol). The contents of
the tubes were shaken on a rotary shaker for 30 min, and centrifuged at 1500g
for 3 min. The dichloromethane was transferred to fresh glass tubes and
evaporated under nitrogen at ambient a temperature. The residues were recon-
stituted in HPLC mobile phase Buffer A (300ml of a mix of 25% (v/v)
methanol and 75% (v/v) distilled water).
Quantification of hydroxylated testosterone metabolites by uv-HPLC.
The analytical methodology for quantifying testosterone metabolites was based
on the method of Funae and Imoaka (13) as previously described by Ekins et
al. (14). Samples of metabolites were run through a heated (50°C) Waters C18
Novapak column (4mm packing, 3.93 150 mm, Part No. 86344) from the
Millipore Corporation, Milford, MA. An Upchurch guard column (2cm,
C130B Anachem, Luton) with a 2-mm i.d., packed with C18 column packing
preceded the main column. The mobile phase used for metabolite separation
consisted of two buffers (A1 B). Buffer A was a mix of methanol (25% v/v)
and distilled water (75% v/v), and buffer B was a mix of methanol (63.5% v/v),
distilled water (35% v/v), and acetonitrile (1.5% v/v). The mobile phase flow
rate was 1mlzmin21 with a gradient program of 25% B during 0–10 min;
50.5%–70% B during 18.5–25 min; 70–100% B during 25–35 min; 100% B
during 35–50% min; 100–25% B during 50–60 min, and 25% B during 60–70
min. The flow rate typically generated a back pressure of 2500 psi.
The HPLC system (LKB, Pharmacia) used a variable wavelength UV
monitor at 254 nm (8) and a Waters Novapack C18 3.9150mm, 4mm
column with guard column. The retention times of the hydroxytestosterone
metabolite standards and testosterone were 6b 5 9.6 min, 15a 5 10.5 min,
7a 5 11.6 min, 16a 5 16.5 min, 16b 5 18.7 min, 11b 5 20.8 min (internal
standard), 2a 5 21.6 min, 2b 5 22.5 min, androstenedione5 27.4, and
testosterone5 29.5 min.
Western blotting. Hepatic microsomal proteins were resolved by SDS-
PAGE with vertical mini-gel electrophoresis equipment (Life Technologies,
Ltd., Paisley, Scotland) using an adaptation of a previously described method
(15). Samples of liver microsomal protein (10mg per lane) were denatured in
10 ml loading buffer (4 ml distilled water, 1 ml 0.5M Tris-HCl, pH 6.8, 0.8 ml
glycerol, 1.6ml 10% w/v SDS, 0.4 mlb-mercaptoethanol, 0.05 ml 0.05% w/v
Pyronin Y) and were separated on a 10% w/v resolving gel. Proteins were
transferred from the polyacrylamide gel to the nitrocellulose sheets by an
electrophoretic method (16). Rabbit anti-rat CYP3A polyclonal antibody (not
cross-reactive with other rat P450s) was a gift from Dr. Colin Henderson,
University of Dundee. CYP3A apoprotein was detected by secondary conju-
gation to the primary antibody by a horseradish peroxidase-linked sheep
anti-rabbit antibody using diaminobenzidine as substrate.
Statistical analysis. Testosterone hydroxylation activity was linear with
respect to protein (0–2 mg) and time (0–10 min). Raw data was transformed
into logarithms due to nonconstant variance. Statistical analysis was carried out
using Dunnettst test (where multiple treatments are compared with saline
control). Differences with ap value equal or less than 0.05 were taken to be
significant.
Results
Testosterone metabolism.The effect of drug administration on
testosterone hydroxylation activities is shown in table 1. RU 486
increased testosterone 2b-hydroxylation (p , 0.01) and 6b-hydroxy-
lation (p , 0.01) approximately 5-fold (table 1). Testosterone 15b-
hydroxylation also increased after RU 486 administration (203
pmolzmgzmin in liver microsomes from rats treated with RU 486
compared with undetectable activity in hepatic microsomes from
treated animals). Dexamethasone increased testosterone 6b-and 2b-
hydroxylation activities 15- to 20-fold, as did administration of dexa-
methasone in combination with RU 486. SR-12813 increased testos-
terone 6b-hydroxylation 9-fold (p , 0.01) and also increased
hydroxylation activity at the 15b (p , 0.01) and 2b (p , 0.01)
positions.
Western blot analysis using an anti-CYP3A antibody.To con-
firm the induction of CYP3A by RU 486 and SR-12813 CYP3A
enzyme protein levels were determined by Western blotting (figs. 2
and 3). In fig. 2 the absence of signal in lanes 1 and 2 (saline
treatment) correlates with the the very low constitutive level of
testosterone 6b-hydroxylation in female rats. Administration of RU
486 induced immunoreactive CYP3A protein as shown in lanes 3 and
4. The greater intensity of immunoreactive staining in lanes 7 and 8
(after administration of RU 486 in combination with dexamethasone)
is similar to the levels observed in microsomes from rats administered
dexamethasone only. In fig. 3, levels of immunoreactive protein are
also undetectable in rats administered saline (lanes 1 and 2) and olive
oil vehicle (5 and 6) only. The signal observed in lanes 3 and 4
confirms the induction of CYP3A enzyme levels by SR-12813. In
both figs. 2 and 3, the levels of enzyme induction by dexamethasone
over control are similar (15- to 20-fold). Inter-individual variation in
immunoprecipitable CYP3A protein (and testosterone 6b-hydroxyla-
tion) increases with the level of induction, as exemplified by the
FIG. 1. Structures of RU 486 and SR-12813
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differences in specific activities (2858 to 4336 pmolzmg21zmin-1)
reported in figs. 1 and 2 after dexamethasone treatment and the large SD
in specific activities after dexamethasone1 RU 486 treatment in table 1.
Discussion
The antiglucocorticoid RU 486 and the hypocholesterolaemic drug
SR-12813 increase hepatic levels of CYP3A enzymes in the female
rat. Evidence from previous CYP3A induction studies on the effects
of antiglucocorticoids (17), and hypocholesterolaemic drugs (9) sug-
gests these drugs increase CYP3A levelsvia separate mechanisms.
The induction of CYP3A gene expression by an intra-cellular
species that stereospecifically recognizes glucocorticoids like dexa-
methasone and anti-glucocorticoids such as pregnenolone 16a-carbo-
nitrile led to the proposal of a “non-classical” mechanism for the
involvement of the glucocorticoid receptor in this process (17). The
inducing effect of RU 486 on CYP3A expression observed in this
study fits in with this hypothesis, especially in the light of evidence
that confirms the antagonism by RU 486 of dexamethasone-induction
of genes regulated by glucocorticoids (18). The anti-glucocorticoid,
pregnenolone 16a-carbonitrile, also induces CYP3A1 gene transcrip-
tion (19). The observation that RU 486 induces CYP3A mRNA levels
TABLE 1
Comparison of rat liver microsomal testosterone hydroxylation after drug treatment
15b 6b 2b 16a 16b
Saline (N 5 7) 0 2276 76 706 79 1366 74 1016 59
Olive oil (N 5 3) 0 1986 28 0 1716 3 896 19
SR-12813 (N 5 4) 4836 117** 18896 330** 3576 79** 194 6 15 1796 13
RU 486 (N 5 4) 2036 58** 909 6 304** 3836 109** 1396 49 2226 62
Dexamethasone
(N 5 7)
6636 157** 33016 703** 11706 237** 2856 80 3026 29*
Dexamethasone
1 RU 486 (N 5 4)
7376 461** 36636 1646** 13586 129** 2386 108 2386 108*
Activities (pmol/mg/min) for each sample of hepatic microsomes were made in duplicate from each liver (N 5 no. animals per group). Values represent the
means6 SD. Statistical analysis comparing multiple treatments against saline control was made using one-way ANOVA followed by Dunnett’st test (*p , 0.05,
** p , 0.01).
FIG. 2. Effect of RU 486 on induction of hepatic micrososomal CYP3A
enzymes by dexamethasone as shown by immunoblot analysis with a
polyclonal anti-CYP3A antibody.
Immunoreactive protein and testosterone hydroxylation activity was deter-
mined in hepatic microsomes from 8 individual rats (2 per treatment group).
For immunoblot analysis microsomal protein (10mg) was electrophoresed on
a sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose,
as described inMaterials and Methods. Testosterone hydroxylation activity
was also determined in liver microsomes from the same batch, as described in
Materials and Methods.
FIG. 3. Effect of SR-12813 on hepatic microsomal CYP3A levels as shown
by immunoblot analysis with polyclonal anti-CYP3A antibody.
Immunoreactive protein and testosterone hydroxylation activity was deter-
mined in hepatic microsomes from 8 individual rats (2 per treatment group).
For immunoblot analysis microsomal protein (10mg) was electrophoresed on
a sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose,
as described inMaterials and Methods. Testosterone hydroxylation activity
was also determined in liver microsomes from the same batch, as described in
Materials and Methods.
759BISPHOPHONATE INDUCTION OF CYP3A: A NEW CLASS OF DRUGS THAT ACT ON HMG-CoA REDUCTASE
in rat, human, and rabbit hepatocytes (20,21) suggests that the mech-
anism responsible is conserved across mammalian species. The hy-
pothesis that nonsteroidal compounds achieve their inducing effects
by increasing the level of circulating endogenous glucocorticoids in
the liver was tested by comparing drug effectsin vivo and in vitro
(22). This study revealed that phenobarbital and phenobarbital-like
inducers of CYP3A induce enzyme levels directly on primary cultures
of hepatocyte monolayers. A subsequent study showed a dose differ-
entiation of drug effect for induction of CYP2B and CYP3A genes
mediated by phenobarbital, clotrimazole, andtrans-nonachlor (23).
These results implicate multiple mechanisms for induction of these
enzymes, which may involve intracellular glucocorticoids (RU 486
antagonizes the phenobarbital-induction of CYP2C6 mRNA in mouse
hepatoma cells (24).
Kocarek et al. (9) reported the induction of CYP3A1-mediated gene
expression by the HMG-CoA reductase inhibitor lovastatin. Lova-
statin induced rat CYP3A1 gene expression directly in primary cul-
tures of rat hepatocytes and potentiates the phenobarbital- and clo-
trimazole-mediated induction but not dexamethasone-mediated
CYP3A1 induction in rat hepatocytes (9), once more indicating that
multiple mechanisms are responsible for CYP3A1 induction. Two
other “statin” drugs, simvastatin (25) and pravastatin (8, 25), increase
the urinary excretion ratio of 6b-hydroxycortisol/cortisol in man, ani
vivomarker of CYP3A activity. Lovastatin also induced CYP3A gene
expression in human and rabbit hepatocytes (21). HMG-CoA reduc-
tase is the rate-limiting enzyme in cholesterol biosynthesis and its
activity is reduced by lovastatin (25)via enzyme inhibition at the
active site and by SR-12813 (26)via an increased degradation of the
enzyme. As SR-12813 is also a potent inducer of CYP3A activity, it
seems possible that there may be an association between the control of
cholesterol biosynthesis and the induction of CYP3A gene expression.
This hypothesis is supported by the fact that either mevalonate, the
immediate product of HMG-CoA reductase, or the regulatory oxys-
terol 25-hydroxycholesterol suppress the lovastatin-mediated induc-
tion of CYP3A1 mRNA (9). Oxysterols have an intracellular role in
the suppression of genes coding for proteins that maintain balanced
cellular cholesterol levels, including HMG-CoA reductase, the LDL
receptor protein (27) and interestingly lanosterol 14-alpha-demethyl-
ase coded by the P450 gene CYP51 (28). It is possible that CYP3A
gene expression is also negatively regulated by oxysterols. In that case
both SR-12813 and lovastatin would induce CYP3A gene expression
by removing the suppressive influence of successive products of
HMG-CoA reductase from mevalonate onwards to oxysterols (29).
The use of cultured hepatocytes would provide an isolated system to
investigate whether phenobarbital but not dexamethasone induction of
CYP3A1 expression is potentiated by SR-12813 (as in the case of
lovastatin (9)). These studies would provide direct evidence for sep-
arate control mechanisms for CYP3A gene expression. Information in
this paper shows that the antiglucocorticoid RU 486 also induces
CYP3A enzyme levels. This compound is structurally and pharmaco-
logically unrelated to SR-12813 but achieves a similar effect. Fur-
thermore, another antiglucocorticoid, pregnenolone 16a-carbonitrile,
is an inducer of CYP3A enzymes in the rat to the same level as the
glucocorticoid dexamethasone (17). The existence of multiple mech-
anisms of control and the involvement of intracellular messengers
such as oxysterols may point to an endogenous role for these enzymes
in addition to the distinct xenobiotic metabolizing role that these
enzymes have.
The results in this paper clearly show that SR-12813, a member of
a new class of hypocholesterolaemic drugs (bisphosphonates) induces
levels of hepatic CYP3A enzymes. Further research is required to
establish whether the CYP3A inducing property of SR-12813 extends
to other bisphosphonates and the mechanism responsible for their
inducing effect.
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